Induction of Robust Diabetes Resistance and Prevention of Recurrent Type 1 Diabetes Following Islet Transplantation by Gene Therapy

Chaorui Tian, Mohammed Javeed I. Ansari, Jesus Paez-Cortez, Jessamyn Bagley, Jonathan Godwin, Michela Donnarumma, Mohamed H. Sayegh and John Iacomini

*J Immunol* 2007; 179:6762-6769; doi: 10.4049/jimmunol.179.10.6762
http://www.jimmunol.org/content/179/10/6762
Induction of Robust Diabetes Resistance and Prevention of Recurrent Type 1 Diabetes Following Islet Transplantation by Gene Therapy

Chaorui Tian, Mohammed Javeed I. Ansari, Jesus Paez-Cortez, Jessamyn Bagley, Jonathan Godwin, Michela Donnarumma, Mohamed H. Sayegh, and John Iacomini

We have previously shown that the development of type 1 diabetes (T1D) can be prevented in nonobese diabetic (NOD) mice by reconstitution with autologous hemopoietic stem cells retrovirally transduced with viruses encoding MHC class II I-A β-chain molecules associated with protection from the disease. In this study we examined whether a blockade of the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) pathway, a major pathway known to control diabetes occurrence, could precipitate T1D in young NOD mice following reconstitution with autologous bone marrow retrovirally transduced with viruses encoding protective MHC class II I-A β-chain molecules. In addition, we examined whether the expression of protective MHC class II alleles in hemopoietic cells could be used to prevent the recurrence of diabetes in mice with pre-existing disease following islet transplantation. Protection from the occurrence of T1D diabetes in young NOD mice by the expression of protective MHC class II I-A β-chain molecules in bone marrow-derived hemopoietic cells was resistant to induction by PD-1-PD-L1 blockade. Moreover, reconstitution of NOD mice with pre-existing T1D autologous hemopoietic stem cells transduced with viruses encoding protective MHC class II I-A β-chains allowed for the successful transplantation of syngeneic islets, resulting in the long-term reversal of T1D. Reversal of diabetes was resistant to induction by PD-1-PDL-1 blockade and depletion of CD25+ T cells. These data suggest that expression of protective MHC class II alleles in bone marrow-derived cells establishes robust self-tolerance to islet autoantigens and is sufficient to prevent the recurrence of autoimmune diabetes following islet transplantation. The Journal of Immunology, 2007, 179: 6762–6769.

Received for publication June 14, 2007. Accepted for publication September 4, 2007.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was supported in part by National Institutes of Health Grants R01 AI44268 and R01 AI43619 and Grant 7-04-RA-45 from the American Diabetes association (to J.I.). M.H.S. is supported by the National Institute of Allergy and Infectious Diseases (PO1 AI041521 and PO1 AI056299) and The Juvenile Diabetes Research Foundation Center Grant on Immunological Tolerance in Type I Diabetes. C.T. is supported in part by an American Society of Transplantation/Roche Basic Science Faculty Development Grant. M.J.A. is supported in part by The American Society of Transplantation/Wyeth Basic Science Faculty Development Grant. J.P.C. is supported by an American Diabetes Association Mentor-Based Minority Postdoctoral Fellowship. J.B. is supported in part by a grant from the Children’s A-T Project (to J.I.). M.H.S. is supported by the National Institute of Allergy and Infectious Diseases (P01 AI041521 and P01 AI056299) and The Juvenile Diabetes Research Foundation Center Grant on Immunological Tolerance in Type I Diabetes. C.T. is supported in part by an American Society of Transplantation/Roche Basic Science Faculty Development Grant. M.J.A. is supported in part by The American Society of Transplantation/Wyeth Basic Science Faculty Development Grant. J.P.C. is supported by an American Diabetes Association Mentor-Based Minority Postdoctoral Fellowship. J.B. is supported in part by a grant from the Children’s A-T Project and an American Society of Transplantation Fujisawa Basic Scientist Career Development Faculty Grant.

1 Address correspondence and reprint requests to Dr. John Iacomini, Ph.D., Transplantation Research Center, Renal Division, Brigham and Women’s Hospital and Children’s Hospital Boston, Harvard Medical School, Boston, MA 02115. E-mail address: jiacomini@rics.bwh.harvard.edu

2 Abbreviations used in this paper: T1D, type 1 diabetes; GAD 65, glutamic acid decarboxylase 65; GVHD, graft-vs-host disease; MBP, myelin basic protein; PD-1, programmed death-1; PD-L, programmed death ligand.

Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00
tolerance as seen with mixed cellular chimera (30, 31). In addition, we have shown that the induction of molecular chimerism can be used to prevent the development of autoimmunity in T1D (31, 33). The expression of diabetes-resistant protective MHC class II I-Aβ-chain molecules in NOD mice following retroviral transduction of autologous bone marrow hemopoietic stem cells prevented the development of autoreactive T cells by intrathymic deletion and protected the mice from the development of diabetes and insulin (31). These data suggest that T1D could be prevented in individuals expressing MHC alleles associated with susceptibility to disease by restoring protective MHC class II expression through the genetic engineering of autologous hemopoietic stem cells.

To further examine the potential clinical utility of using the induction of molecular chimerism to treat T1D, we set out to determine whether protection from disease is robust. Programmed death-1 (PD-1) binds two ligands, programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2). PD-1-PD-L interactions control the induction and maintenance of peripheral T cell tolerance (reviewed in Ref. 34). Studies have shown that PD-1 or PD-L1 but not PD-L2 blockade rapidly precipitated diabetes in prediabetic NOD mice regardless of age and is thus a major pathway that controls diabetes development (35). We therefore used PD-1-PD-L1 blockade as a way to measure whether the protection from disease is robust. We also wished to examine whether this approach, in addition to preventing the development of T1D in genetically prone individuals without pre-existing disease, can be used to treat individuals with pre-existing disease and prevent recurrence after islet transplantation. Accordingly, we examined whether the induction of molecular chimerism and the expression of protective MHC class II alleles on bone marrow-derived cells from NOD mice with pre-existing disease is sufficient to prevent the recurrence of T1D in these mice after treatment and allow for the long-term restoration of normoglycemia through islet transplantation. Our results indicate that protection from diabetes using this approach is resistant to induction through PD-1-PD-L1 blockade. Moreover, expression of the protective MHC class II I-ABβ chain on hemopoietic cells following retroviral transduction of bone marrow is sufficient to prevent the destruction of transplanted syngeneic islets and therefore the recurrence of diabetes in NOD mice with pre-existing T1D despite the presence of peri-insulitis within the islet transplant.

Materials and Methods

**Mice**

NOD/LtJ (NOD) and NOD.CB17-Prkdc<sup>SCID</sup>/J (NOD.SCID) mice were purchased from The Jackson Laboratory. All experiments were performed in accordance with institutional guidelines.

**Vector construction and production of recombinant retroviruses**

The construction of the vector encoding MMP-1Aβ-d-GFP and the production of a recombinant retrovirus was described previously (31). Viruses preparations tested negative for helper virus contamination. The titers of retroviral supernatants used in this study were between 3 and 5 × 10<sup>6</sup> infectious particles per ml. The control MMP-GFP retrovirus was kindly provided by Dr. R. Mulholland through the Harvard Gene Therapy Initiative, Harvard Institute of Human Genetics (Boston, MA).

**Bone marrow transplantation and transplantation**

Bone marrow cells were harvested from NOD mice as described previously (29). Briefly, 3- to 4-wk-old female NOD mice were injected via the tail vein with 150 mg/kg 5-fluorouracil. Seven days later the mice were sacrificed and bone marrow was harvested from the hind limbs by flushing with sterile medium. The bone marrow was filtered through sterile nylon monofilament mesh, and RBC lysed. The cells were then transduced as described (31). At the end of the transduction period the frequency of mature lymphocytes in the bone marrow preparation was usually <1%. A multiplicity of infection of 2 for MMP-1Aβ-d-GFP and 3 for MMP-GFP-transduced cells was used. After 96 h in culture, cells were harvested, washed, and 4 × 10<sup>6</sup> cells were injected i.v. into preconditioned recipients. Recipients were preconditioned with 11 g of whole body irradiation 1 day before bone marrow transplantation.

**Antibodies and PD-1-PDL-1 blockade**

A mAb specific for I-A<sup>d</sup> (39-10-8) was obtained from BD Pharmingen. mAbs specific for FoxP3 (FJK-16s) were obtained from eBioscience. A rabbit anti-mouse CD3 Ab was obtained from Cell Marque. Guinea pig anti- porcine insulin Abs was obtained from DakoCytomation. The anti- mouse PD-L1 mAb (MH6; rat IgG2a) was generously provided by Dr. Miyuki Azuma (36) and manufactured and purified by BioExpress. Rat IgG (Sigma-Aldrich) was used as a control. Anti-mouse PD-L1 mAb or rat IgG were given i.p. as follows: 500 µg on day 0 followed by 250 µg on days 2, 4, 6, 8, and 10 (35).

**In vivo depletion of CD25<sup>+</sup> T cells**

To deplete CD25<sup>+</sup> T cells, mice were injected i.p. with 0.5 mg of the anti-CD25 Ab PC61 (manufactured and purified by BioExpress) every 3 days. A total of four doses was given. Depletion of CD25<sup>+</sup> T cells was confirmed by flow cytometry after staining blood cells with the anti-CD25 Ab 7D4 (BD Pharmingen) 5 days after the completion of Ab treatment. Staining with 7D4 is not blocked by PC61.

**Blood glucose levels and insulin treatment**

Blood glucose levels were monitored weekly before and daily after the onset of diabetes using a BD Logic blood glucose monitor (BD Biosciences). Two consecutive readings of >250 mg/dl were considered to be indicative of the development of hyperglycemia. Diabetic NOD mice were maintained with a daily injection of 2–6 U of insulin, a 1:1 mixture of Humulin U and Humulin L (Eli Lilly).

**Islet transplantation**

After naive female NOD mice developed T1D spontaneously, mice were reconstituted with retrovirally transduced bone marrow cells. Five to six weeks after reconstitution, the mice were confirmed to be diabetic by suspending insulin injections and demonstrating that the blood glucose level was >250 mg/dl. Mice were then transplanted with ~1000 islets from female NOD.SCID donors under the renal capsule as described previously (37). This islet dose was used to allow us to observe a transient reversal of hyperglycemia in control mice and to rule out technical failures of the islet transplant procedure. Islet graft function was assessed by blood glucose measurements daily for 1 wk and then three times a week until the mice were sacrificed. Reversal of T1D was defined as blood glucose levels of <200 mg/dl after islet transplantation. Graft rejection was defined as blood glucose levels of >250 mg/dl on two consecutive days. Rejection was also confirmed by histology.

**ELISPOT**

Cytokine ELISPOT assays were performed as described previously (31). Briefly, BVD-1D11 (anti-IL-4) and R4-6A2 (anti-IFN-γ) (In vitro Life Technologies) were used at 10 µg/ml to coat plates. Splenocytes (10<sup>5</sup>) were added to each well. Cells were cultured overnight with 0.1 mg/ml insulin (Sigma-Aldrich) and the myelin basic protein (MBP) peptide (peptide 85–99; ENPVHFKNIWTTR) or the glutamic acid decarboxylase 65 (GAD 65) peptide (peptide 206–220; TYEIAVPFVLLEVT). Peptides were obtained from Invitrogen Life Technologies. Cytokine production was detected using 10 µg/ml biotinylated BVD-24G2 (anti-IL-4) and XMG1.2 (anti-IFN-γ) (Invitrogen Life Technologies). Assays were performed in triplicate and averaged. To calculate the specific response to GAD 65 and insulin, the average background response to MBP protein was subtracted. There was no significant difference in the response to MBP peptide between the groups (not shown).

**Histology**

Ninety days after islet transplantation or when the mice became diabetic, islet grafts along with the kidney were collected from recipients reconstituted with either MMP-1Aβ-d-GFP- or MMP-GFP-transduced bone marrow and fixed in buffered formalin. Immunohistochemistry staining was performed using 5-µm thick paraffin-embedded tissue sections. Briefly, slides were then treated with 1.0 mM EDTA (pH 8.0) (Zymed Laboratories) in a steam pressure cooker (Biocare Medical Decloaking Chamber) followed by washing in distilled water. All further steps were performed at room temperature in a hydrated chamber. Slides were...
pretreated with Peroxidase Block (DakoCytomation) for 5 min to quench endogenous peroxidase activity. Primary rabbit anti-CD3 Ab (Cell Marque) or primary rat anti-FoxP3 Ab (eBioscience) were applied in DakoCytomation diluent for 1 h. Slides were washed in 50 mM Tris-Cl (pH 7.4) and detected with an anti-rabbit EnVision + kit (DakoCytomation) or polyclonal biotinylated rabbit anti-rat Ig (DakoCytomation) as per the manufacturer’s instructions. After further washing, immunoperoxidase staining was developed using a DAB chromogen (3,3′-diaminobenzidine in chromogen solution; DakoCytomation) and counterstained with hematoxylin. For insulin staining, tissue sections were stained with guinea pig anti-porcine insulin Ab for 15 min and stained with a biotinylated goat anti-guinea pig secondary Ab (Vector Laboratories) for 30 min. Sections were developed using an avidin-biotin complex (ABC) solution and 3,3′-diaminobenzidine (Vector Laboratories) and counterstained with hematoxylin. Samples were then analyzed by bright field microscopy.

**Results**

**Expression of retrovirally encoded MHC class II-GFP fusion genes following reconstitution of NOD mice with transduced syngeneic bone marrow**

To examine the role of MHC class II in providing protection from a recurrence of diabetes following islet transplantation, genetic engineering of bone marrow hemopoietic stem cells was used to achieve the expression of retrovirally encoded MHC class II β-chains associated with protection from disease in autologous hemopoietic cells of NOD mice. Bone marrow was harvested from 3- to 4-wk-old female NOD/LtJ mice (hereafter referred to as NOD mice) treated (median onset time 3.7% (p = 0.001 between groups; Fig. 2). This ratio was similar to that of untreated naive NOD mice in our colony (not shown). Consistent with our previous data showing that a PD-1-PD-L1 blockade precipitates diabetes in an accelerated fashion (35), 75% of mice reconstituted with control MMP-GFP-transduced bone marrow developed hyperglycemia within 85 days following anti-PD-L1 treatment (median onset time >180 days, n = 11; Fig. 2). These data suggest that prevention of TID in young NOD mice induced by molecular chimerism is resistant to precipitation by a PD-1-PD-L1 blockade.

**Expression of protective MHC class II genes in NOD mouse bone marrow-derived cells prevents recurrence of T1D following islet transplantation**

We next set out to examine the effectiveness of inducing molecular chimerism by examining whether the expression of retrovirally transduced diabetes-protective MHC class II genes in bone marrow-derived cells can prevent diabetes recurrence following islet transplantation. Fourteen- to 22-wk-old spontaneously diabetic female NOD mice with pre-existing disease (blood glucose level of >250 mg/dl) were maintained with daily injections of 2–6 U of a 1:1 mixture of Humulin U and Humulin L. The mice were lethally irradiated (11 gray) and reconstituted with 4 × 10⁶ MMP-IAβ-d-GFP or MMP-GFP virus-transduced syngeneic bone marrow cells from 3 to 4 wk old nondiabetic female donor NOD mice. Four weeks after bone marrow transplantation, 20.3 ± 3.7% (n = 16) of PBMC from mice reconstituted with MMP-GFP-transduced bone marrow expressed GFP. In these mice, both MHC class II+ and well as class II− cells derived from transduced progenitors expressed GFP (Fig. 1B). In mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow, 19.5 ± 4.2% (n = 16) of PBMC...
from mice expressed GFP (Fig. 1B), indicating similar levels of transduction compared with control mice. Although both MHC class II<sup>+</sup> and well as class II<sup>-</sup> cells derived from transduced progenitors expressed GFP in these mice, we wish to point out that the transduced MHC class II β-chain-GFP fusion protein is expressed on the surface of cells committed to MHC class II expression as previously reported (31). At this time point, the mice were confirmed to be diabetic by withdrawing insulin treatment and ensuring that the blood glucose level was >250 mg/dl the day before islet transplantation. The mice were then transplanted with ~1000 islets from NOD.CB17-Prkdc<sup>scid</sup>/J (NOD.SCID) donor mice under the left kidney capsule. NOD-SCID islets were used to prevent the possibility of transferring islet-infiltrating or diabetogenic lymphocytes, thereby allowing unambiguous assessment of the impact of our approach on host autoreactivity. Blood glucose levels were then monitored daily for 1 wk and then three times per week thereafter.

Mice (n = 6) reconstituted with MMP-GFP-transduced bone marrow became normoglycemic within 24 h after islet transplantation; however, all six of these mice developed recurrent diabetes by day 9 after islet transplantation due to recurrent autoreactivity and were sacrificed (median time of onset = 3 days; Fig. 3). In contrast, five of six mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow were protected from the recurrence of diabetes for at least 90 days after islet transplantation, at which time point the experiments were terminated (p < 0.01 between groups, median time of onset >90 days after islet transplantation, n = 6; Fig. 3). One mouse from the group of six mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow developed recurrent diabetes 42 days after islet transplantation. Interestingly, the mouse reconstituted with MMP-IAβ-d-GFP that developed recurrent T1D 42 days after islet transplantation showed a dramatically lower frequency of MMP-IAβ-d-GFP-expressing cells in its blood based on GFP fluorescence as assessed by flow cytometry when compared with that of other mice in the same group (≤5% of nucleated cells in blood).

Expression of retrovirally encoded MHC class II-GFP fusion genes in NOD mouse bone marrow-derived cells prevents the destruction of islet grafts by autoreactive T cells

We next examined transplanted islets histologically to further assess the degree of protection from recurrent disease. Mice reconstituted with MMP-IAβ-d-GFP or control MMP-GFP-transduced bone marrow that received an islet transplant were sacrificed 90 days after transplantation or when the mice developed recurrent diabetes (n = 6 per group). Tissue sections of islet grafts were then prepared and stained with H&E or anti-insulin, anti-CD3, and anti-Foxp3 Abs. Islet grafts from mice reconstituted with MMP-GFP-transduced bone marrow with recurrent diabetes and a blood glucose level of 250–300 mg/dl on day 1 after islet transplantation (far left column) or with a blood glucose level >300 mg/dl on day 3 after islet transplantation (second column from left) showed significant mononuclear cell infiltration, CD3<sup>+</sup> T cell infiltration, and decreased (far left column) or absent (second column from left) storage of insulin. In contrast, islets from mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow showed normal levels of insulin storage in the presence (third column from left), glucose level of >600 mg/dl at the time of reconstitution) or absence (far right column, glucose level of ~300 mg/dl at the time of reconstitution) of peri-insulitis. Shown are representative sections from three independent experiments.
FoxP3+ cells were only found in one mouse in the early stage of rejection (Fig. 4, far left column). In contrast, islet grafts from mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow showed either normal islets without insulitis or nondestructive peri-insulitis in which CD3+ T cell infiltration was observed around islets (Fig. 4). Insulin storage appeared to be intact in all islet grafts, including those with peri-insulitis. FoxP3+ cells were found in those islet grafts with peri-insulitis, suggesting that FoxP3+ regulatory cells might play a role in preventing the rejection of islet grafts in these mice. Overall, these data suggest that expression of the diabetes-protective MMP-IAβ-d-GFP gene prevents the destruction of islet grafts by autoreactive T cells.

**T cells in diabetic NOD mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow following islet transplantation are not responsive to islet self-Ags**

We also examined the frequency of self-Ag reactive T cells in the spleens of islet transplant recipients sacrificed for histological analysis of their islet grafts. Splenocytes were stimulated overnight with either insulin (whole protein), peptide 206–220 from GAD 65, or peptide 85–99 from MBP as a control in ELISPOT assays. Both the GAD 65 and MBP peptides bind I-Aα7 (38). The GAD 65 peptide has been proposed to be a potential self-Ag peptide in NOD mice (39). NOD mice with pre-existing diabetes that were reconstituted with MMP-GFP-transduced bone marrow contained a high frequency of splenocytes that were able to secrete IFN-γ (298 ± 82/10^6 cells) and IL-4 (100 ± 67/10^6 cells) in response to the GAD 65 peptide (Fig. 5, n = 4). In contrast, we were unable to detect significant production of either IFN-γ (9 ± 8/10^6 cells, p < 0.01) or IL-4 (7 ± 7/10^6 cells, p < 0.01) in response to GAD 65 peptide by splenocytes from mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow (Fig. 5). Similarly, a significantly higher number of splenocytes from NOD mice with pre-existing diabetes that were reconstituted with MMP-GFP-transduced bone marrow produced IFN-γ (815 ± 84/10^6 cells) and IL-4 (305 ± 83/10^6 cells) in response to insulin, while cells from NOD mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow had significantly lower number of splenocytes producing IFN-γ (21 ± 7/10^6 cells, p < 0.01) and IL-4 (11 ± 9/10^6 cells, p < 0.01) in response to insulin (Fig. 5). These data suggest that expression of a protective MHC class II β-chain in bone marrow-derived cells is able to prevent the recurrence of autoimmunity in diabetic NOD mice.

**Prevention of diabetes recurrence following islet transplantation in mice expressing protective MHC class II alleles is resistant to diabetes induction by PD-1-PD-L1 blockade and the depletion of CD25+ cells**

To determine whether the prevention of disease recurrence following islet transplantation conferred by the expression of protective MHC class II β-chains is robust, we examined whether blockade of the PD-1-PD-L1 pathway could precipitate the recurrence of T1D. Fourteen- to 22-wk-old spontaneously diabetic female NOD mice with pre-existing disease (blood glucose >250 mg/dl) were maintained with daily injections of 2–6 U of insulin, lethally irradiated (11 gray), and reconstituted with 4 × 10^6 MMP-IAβ-d-GFP virus transduced syngeneic bone marrow cells from 3- to 4-wk-old nonobese female donor NOD mice as described above. Four weeks after bone marrow transplantation, the mice were then transplanted with ~1000 NOD-SCID islets under the left kidney capsule and blood glucose levels were then monitored as described above. At the time of islet transplantation, day 0, the mice were treated with 500 µg of anti-PD-L1 mAb or rat IgG followed by 250 µg on days 2, 4, 6, 8, and 10. As observed for young mice in which expression of protective MHC class II chains prevented T1D induction by PD-1-PD-L1 blockade (Fig. 2), mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow in which normoglycemia was restored following islet transplantation were protected from PD-1-PD-L1 blockade-induced diabetes (Fig. 6A).

Based on the observation that FoxP3+ cells are observed in islet grafts from mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow that exhibit nondestructive insulitis (Fig. 4), we next set out to determine whether the maintenance of normoglycemia following islet transplantation in mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow is controlled by regulatory T cells. To this end, spontaneously diabetic NOD mice were reconstituted with MMP-IAβ-d-GFP-transduced bone marrow and then transplanted with NOD-SCID islets as described above. On the day of islet transplantation, mice were treated with the anti-CD25-depleting Ab PC61 or rat Ig as a control and the depletion of CD25+ T cells was analyzed as described in Materials and Methods. Analysis of CD25 depletion by cell surface staining and flow cytometry revealed that PC61 treatment resulted in the depletion of >95% of CD25+ T cells in blood (not shown). Although FoxP3+ cells are present in islet grafts from mice reconstituted...
Merism in prediabetic individuals is robust and able to resist interventions that normally affect the ability to maintain peripheral tolerance. Anti-PD-L1 mAb treatment failed to precipitate the occurrence of T1D in young NOD mice following reconstitution with autologous bone marrow retrovirally transduced with viruses encoding protective MHC class II I-A β-chain molecules. These data suggest that the induction of molecular chimerism by gene therapy is a robust way to re-establish self-tolerance in prediabetic NOD mice. Moreover, these data suggest that the protection provided is able to resist alterations in peripheral tolerance induced by the blockade of the PD-1-PD-L1 pathway and that the tolerance induced through this approach involves the deletion of self-reactive T cells as we have suggested previously (31).

A major issue in the treatment of T1D is the ability to prevent the recurrence of autoimmunity. Indeed, the inability to prevent the recurrence of autoimmunity has significantly impacted the ability to treat T1D through islet transplantation. Our data suggest that the reconstitution of NOD mice with pre-existing disease using autologous bone marrow transduced with retroviruses carrying the MHC class II β-chain genes associated with protection from diabetes prevents the recurrence of autoimmunity following islet transplantation. As observed for young mice in which the expression of protective MHC class II chains prevented disease, prevention of the recurrence of T1D following islet transplantation was resistant from disease induction by blocking the interaction of PD-1 and PD-L1 suggesting that protection against recurrent diabetes is also robust.

Expression of a diabetes-protective MHC class II β-chain prevented the function of self-reactive T cells that respond to islet autoantigens. Islet grafts from these mice appeared either completely devoid of infiltration or contained a nondestructive peri-insulitis. In either case, insulin storage and islet architecture were normal. Our inability to detect functional autoreactive T cells in these mice by ELISPOT assays may be due to either negative selection of autoreactive clones, regulation of these cells by peripheral mechanisms, or both. However, depletion of CD25+ cells did not precipitate diabetes in these mice. Although this would suggest that CD25+ regulatory T cells do not play a role, it is important to keep in mind that activated T cells also express CD25; therefore, the lack of disease induction could be related to the depletion of recently activated effectors. Alternatively, it is possible that the expression of protective MHC class II genes in bone marrow-derived cells leads to the negative selection of autoreactive T cells. Indeed, we have previously demonstrated that the induction of molecular chimerism by the reconstitution of NOD mice with autologous bone marrow cells transduced with MMP-Iαβ-d-GFP results in negative selection of autoreactive T cells in the thymus (31). Bone marrow-derived cells lack the ability to positively select T cells (40–42) but are potent mediators of negative selection (43, 44). We therefore favor the notion that the reestablishment of tolerance to self in molecular chimeras involves, at least in part, negative selection of newly developing autoreactive T cells. In this context, it is possible that CD25+ cells capable of controlling disease are able to develop but are not essential for controlling disease given the reestablishment of the ability to efficiently mediate negative selection of autoreactive T cells. We are presently analyzing whether the induction of molecular chimerism leads to the generation of regulatory T cells.

In our previous work (31), we demonstrated that the pancreata of young NOD mice protected from disease occurrence through the induction of molecular chimerism were free of cellular infiltrates and exhibited normal insulin storage. In this study we observed that after the reversal of pre-existing hyperglycemia in NOD mice by islet transplantation, significant peri-insulitis persisted in some of the mice reconstituted with MMP-Iαβ-d-GFP-transduced
bone marrow, although these mice remained normoglycemic. This result may suggest that although the thymus is not able to produce newly developing autoreactive T cells in molecular chimeras due to central deletion, the pre-existing self-reactive memory cell pool may be large enough to survive irradiation and persist but does not destroy the islet grafts in the recipients. Indeed, we have shown that existing T cells are resistant to irradiation (45). It is possible that, in the mice with advanced T1D, peripheral autoreactive T cells are not susceptible to irradiation or deletion, accounting for peri-insulitis in the islet grafts. However, the peri-insulitis observed appears to be nondestructive, which may be due to regulation by Foxp3+ cells observed infiltrating into the islet grafts. We are presently attempting to define the role of islet graft-infiltrating Foxp3+ cells.

We did observe an instance in which a mouse reconstituted with MMP-IAβ-d-GFP-transduced bone marrow showed no significant cell infiltration within the transplanted islet graft and intact insulin storage. In this animal, we did not initially observe severe hyperglycemia, and the blood glucose level was just above the cutoff point of 250 mg/dl when reconstituted with MMP-IAβ-d-GFP-transduced bone marrow. This supports the idea that the size of the pre-existing autoreactive T cell pool might be a key factor in the development of peri-insulitis in the islet grafts of mice reconstituted with MMP-IAβ-d-GFP-transduced bone marrow. Indeed, as suggested by other investigators, there may be a qualitative change in autoreactive T cells after the development of overt diabetes in the NOD (46). The absence of Foxp3+ cells in the islet graft of this mouse further indicates that the mechanism of protection from recurrent diabetes involved the deletion of autoreactive T cells. If the pre-existing autoreactive T cell pool is relatively small, as in this instance, lethal irradiation may reduce the existing mature autoreactive T cell pool and prevent the development of peri-insulitis. In contrast, if the pre-existing autoreactive T cell pool is large as those in the mice in which glucose levels were much higher at the time of reconstitution, irradiation-resistant autoreactive T cells may persist in a significant number and will contribute to the development of peri-insulitis. We also observed that one of the six mice reconstituted with MMP-IAβ-d-GFP developed recurrence of T1D 42 days after islet transplantation. This particular mouse showed dramatically lower levels of MMP-IAβ-d-GFP expression in its blood when compared with that of other mice in the same group, which may have led to the failure to re-establish tolerance to self. This result suggests that a threshold level of protective MMP-IAβ-d-GFP expression must be achieved to overcome autoimmunity. Indeed, we have recently shown in molecular chimeras that persistence of Ag is important in maintaining tolerance (47).

Many gene therapy strategies aimed at preventing autoimmune diabetes by the introduction of cytokine genes or by the blockade of costimulatory molecules have achieved promising results in animal models (48–61). However, to our knowledge gene therapy strategies have in general been unsuccessful in establishing a long-term reversal of diabetes in subjects with well-established pre-existing T1D (61).

Most importantly, many previously described strategies attempt to prevent autoimmunity by modifying cytokine or costimulatory profiles but do not address the issue of preventing the generation and development of autoreactive T cells themselves. Such strategies will likely cause nonspecific immunosuppression in recipients. By using gene therapy to introduce a diabetes-protective MHC class II β-chain allele, we suggest it may be possible to specifically target autoreactive T cells while sparing general immunocompetence (30, 31).

Islet transplantation is a promising way to cure T1D. However, for islet transplantation to be successful as a long-term cure for T1D (2, 3, 62) it is necessary to overcome the underlying autoimmunity that leads to rejection of the transplanted islets (4). Our results indicate that the introduction of a diabetes-protective MHC class II β-chain on bone marrow cells is sufficient to reverse disease following islet transplantation and prevent its recurrence. Because this approach involves genetic modification of autologous hematopoietic progenitors to establish molecular rather than cellular chimerism, problems associated with the transplantation of allogeneic bone marrow, such as GVHD, are eliminated. We suggest that these results may therefore be of clinical significance in the context of islet transplantation for patients with T1D. Our results are a proof of principle that the induction of molecular chimerism can be used to treat T1D. A major component of moving this approach forward is to develop nonmyeloablative conditioning regimens that would permit the engraftment of genetically modified bone marrow. For individuals with preexisting disease, an interesting issue will be whether the ability of nonmyeloablative conditioning regimens to control or reduce preexisting autoreactive T cells has an impact in terms of being able to prevent disease recurrence. As suggested by others in the context of aloreactivity, conditioning regimens that permit T cell apoptosis may play an important role in reducing the size of autoreactive T cell clones and the development regulatory T cells that permit long-term graft survival (63, 64). In the context of T1D, using conditioning regimens that result in a debulking of pre-existing autoreactive T cells and the development or expansion of regulatory T cells may also be important for the success of the approach we have developed.

Acknowledgments

We thank Drs. Richard C. Mulligan and Jeng-Shin Lee for providing the MMP retroviral vector, the packaging system, and technical advice, as well as the Harvard Gene Therapy Initiative Vector Core, supported in part by the Association Francaise contre les Myopathies (AFM), for the production of retroviruses. We also thank the Specialized Histopathology Core Laboratory of the Dana-Farber Cancer Center (through National Institutes of Health/National Cancer Institute Grant P30 CA6516) for assistance with histological studies.

Disclosures

The authors have no financial conflict of interest.

References


